You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》美銀證券升石藥(01093.HK)目標價至6元 重申「跑輸大市」評級
阿思達克 06-02 11:21
美銀證券發表研究報告指,石藥(01093.HK)今年首季收入按年跌21.9%,當中成品藥、原料藥、功能食品及其他類別的收入分別按年跌27.3%、升14.6%及跌8.9%。集團早前公佈正就3項潛在的授權交易進行磋商, 每項潛在交易項下,可能應付予集團的潛在首付款、潛在開發里程碑付款及潛在商業化里程碑付款,合計可能達到約50億美元。而其中一項潛在交易項目前已處於後期階段,預計將於6月完成。 該行將以上潛在交易中約10億美元的預付款以納入考量範圍,但基於首季集團關鍵藥物的疲弱表現,調低現有產品的全年銷售預測,並分別將2025及26年的總收入預測上調21%及下調1%、2025至27年每股盈利預測分別上調89%、下調5%及下調2%。目標價由5.1元升至6元,但重申「跑輸大市」評級,因目前的產品組合面臨銷售壓力。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account